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AN INVESTIGATION INTO STATINS, PCSK9 INHIBITORS, AND OTHER 
CURRENT CHOLESTEROL TREATMENTS  
MARK E. KILEY 
ABSTRACT 
 Hypercholesterolemia is one of the most prevalent, yet underdiagnosed diseases 
faced by the medical community today.  Its prevalence can largely be attributed to diet, 
lack of exercise, and lifestyle choices such as smoking or drinking, but there is also a 
genetic component.  Familial Hypercholesterolemia is the genetic disorder in which a 
person is unable to properly eliminate levels of low-density lipoprotein, mostly due to an 
ineffective receptor in the liver.  Hypercholesterolemia has been positively correlated 
with the prevalence of cardiovascular disease, and patients with the severe homozygous 
familial hypercholesterolemia typically have abbreviated lifespans.  In these situations, 
and also those less acutely dire, it’s necessary to rely on medication to help maintain 
one’s cholesterol levels to within low risk ranges. 
 High does statin therapy has been shown to be the most effective therapy for 
maintaining LDL cholesterol.  It has become the standard regardless of the cause of 
hypercholesterolemia because of its few side effects, its high tolerability, its ease of 
administration, its safety, and most of all because of its immense efficacy.  This has not, 
however, prevented the exploration into other types of cholesterol therapies that may 
work in concurrence with statins.  Drug classes such as PCSK9 inhibitors, ApoB 
inhibitors, MTP inhibitors, and thyromimetics have all been explored with varying 
success. 
  vi
 Each of these potential therapies has a separate mechanism of action, allowing for 
modulation in conjunction with statins.  PCSK9 inhibitors and ApoB inhibitors appear to 
provide the most upside by virtue of LDL lowering capabilities, followed by a drug 
known as ezetimibe that reduces dietary cholesterol uptake in the gut.  MTP inhibitors 
have been shown to be effective therapies for homozygous familial hypercholesterolemia 
specifically due to their function of lowering LDL particle creation rather than LDL 
receptor number or function as statins and PCSK9 inhibitors do.  Thyromimetics have yet 
to yield an effective therapy for cholesterol treatment, but the hope remains alive that this 
could come to fruition in the future. 
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I. INTRODUCTION 
 Cholesterol is a vital compound in the body for maintaining the structure and 
function of human cells.  Cholesterol is also used as a precursor for bile acids, hormones, 
and vitamin D. (Martin et al., 2012)  Counter to popular belief, most cholesterol in the 
body is created by the liver and only a small percentage is obtained through diet.  Despite 
these vital physiological uses, too much cholesterol in the body becomes detrimental to 
good health; only relatively low levels are required to meet the need for its appropriate 
biological functions (Martin et al., 2012). 
Not all cholesterol is created equal; various classes of cholesterol have been 
defined by their role and how they are packaged.  These types of cholesterol differ in the 
types of lipoproteins on their surfaces, the amount of triglyceride they store, and whether 
they remain in the liver for excretion or use or are sent to circulate for use in peripheral 
tissues.  The two widely known types of cholesterol are what have become known 
colloquially as “bad cholesterol,” or low-density lipoproteins (LDL) and “good 
cholesterol” or high-density lipoproteins (HDL).  LDL cholesterol is not formed in a 
vacuum, but rather another type of cholesterol known as very low-density lipoprotein 
(VLDL) gets broken down by lipases to form intermediate-density lipoprotein (IDL) 
which eventually gets further broken down into LDL.  LDL functions to carry cholesterol 
out to the tissues of the body, while HDL has been identified as having the reverse 
function of picking up cholesterol from the body and returning it to the liver to be either 
repackaged and repurposed or excreted.  The monitoring and balancing of HDL and LDL 
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levels in the blood has emerged as a reliable part of examining one’s cardiovascular 
health and its monitoring and managing has emerged as a large field in healthcare. 
Long term cholesterol imbalance, or dyslipidemia, can lead to atherosclerosis, 
heart disease, and liver disease among other health concerns.  Dyslipidemia has become a 
more widespread issue in the United States and other first world countries with the 
increased prevalence of diets high in salt and fats (O’Keefe et al., 2004).  While the best 
medicine for maintaining healthy cholesterol levels is through proper diet and exercise, 
this expectation sometimes cannot be met sufficiently or is still too ineffective and then it 
becomes important to consider supplementing one’s lifestyle alterations with medication.   
Various types of drugs have been developed for the long term regulation of 
cholesterol (Centre (UK), 2014).  In the 1970’s a class of drugs known as statins was 
developed from fungi as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase in the liver and their use on humans began in the 1980’s 
(Centre (UK), 2014).  Since this time many types of statins have been developed.  These 
drugs have long been considered the gold standard of cholesterol management when used 
independently, but recent evidence indicates a combination therapy of statins alongside 
other types could yield even better outcomes for patient populations.   
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Apolipoprotein 
B (ApoB) inhibitors, Microsomal Triglyceride Transferase Protein (MTP) inhibitors, and 
thyromimetics are each drug classes with different mechanisms of action that when 
coupled with statins could further improve one’s cholesterol and overall health.  This 
thesis intends to investigate each medication’s mechanism of action, their use in 
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combination for treating hypercholesterolemia, and the potential for side effects and 
cardiovascular risk with each. 
Hypercholesterolemia 
Circulating levels of cholesterol in the blood are measured most commonly by the 
concentrations of HDL, LDL, and total cholesterol.  The National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) determined that the management of 
LDL levels is the most important treatment goal for lowering the risk of developing 
cardiovascular disease.  Table 1 summarizes the appropriate levels for LDL, HDL, and 
total cholesterol in normal individuals as set by the NCEP ATP III and also allow for an 
understanding of what levels constitute an increased risk of cardiovascular disease 
(CVD).  
Table 1. NCEP ATP III Guidelines for ideal and at risk cholesterol levels (NCEP ATP-
III Cholesterol Guidelines -- Cholesterol 2.0 - SCYMED, 2002). 
LDL Cholesterol Total Cholesterol HDL Cholesterol 
<100 Optimal <200 Desirable <40 Low 
100-129 Near optimal/above 
optimal 
200-
239 
Borderline 
high 
>60 High 
130-159 Borderline high >240 High 
160-189 High 
>190 Very High 
 
Lifestyle preferences including smoking, diets high in salt or fats, alcohol abuse, 
and lack of exercise all contribute to an increase in LDL and overall cholesterol levels.  
Also included as major risk factors are hypertension (where blood pressure is greater than 
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140/90 mmHg), usage of an antihypertensive medication, an age of older than 45 in men 
and 55 in women, and a family history of CHD (NCEP ATP-III Cholesterol Guidelines -- 
Cholesterol 2.0 - SCYMED, 2002).  Dyslipidemia also can develop secondary to obesity, 
kidney disease, hypothyroidism, liver disease, and diabetes (NCEP ATP-III Cholesterol 
Guidelines -- Cholesterol 2.0 - SCYMED, 2002).  Patients diagnosed with dyslipidemia 
whose cause is not of a genetic nature often can manage their condition independent of 
medication and can significantly lower the risk of cardiovascular events (CE) with 
lifestyle changes and proper diet. 
Normal LDL levels range from as low as 50 mg/dL to 115 mg/dL in healthy 
adults.  Studies have shown that LDL levels of 50 mg/dL were once the norm amongst 
native populations living as hunters and gathers, which adults today eating a typical 
western diet boasts an average of 130 mg/dL (O’Keefe et al., 2004).  This high average 
has culminated in 40-50% of men and women accruing atherosclerosis by the age of 50 
(O’Keefe et al., 2004).  With evidence pointing to a “lower is better” type of mentality 
when approaching LDL cholesterol, it’s been speculated that a target as low as 50 to 70 
mg/dL would reduce cardiovascular risk secondary to dyslipidemia to near zero levels 
and could, in fact, boost longevity (O’Keefe et al., 2004).  Figure 1, adapted from 
O’Keefe’s work, depicts the drastic rise in mean LDL when compared against those of 
neonates, hunter-gatherer predecessors, and animal models.   
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Figure 1. Modern Westernized Adult American total cholesterol and LDL levels 
compared against evolutionarily representative groups (O’Keefe et al., 2004). 
 
Genetic predispositions do, however, make up a large percentage of diagnosed 
cases of hypercholesterolemia that require medication to manage.  As dyslipidemia’s 
development has a longer time course from lifestyle choices, younger patient populations 
presenting with dyslipidemia are more often due to genetic predisposition (Cuchel et al., 
2013; Soutar and Naoumova, 2007) .  Balancing cholesterol becomes of particular 
importance in patients with these genetic predispositions, known collectively as familial 
hypercholesterolemia (FH).  FH typically presents as a mutation in the LDLR gene, but 
can also occur as ApoB mutations, and PCSK9 mutations; while it was initially thought 
that FH resulted from an overproduction of cholesterol, it is now understood that it results 
from an inability to clear LDL properly in the body (Soutar and Naoumova, 2007).  FH 
follows mendelian genetics with a co-dominant transmission; parents carrying a recessive 
allele have the ability to yield children with heterozygous or homozygous genotypes 
(HeFH and HoFH respectively).  FH is most easily recognized by concurrent generalized 
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Hunter-Gatherer Humans
Wild Primates
Wild Mammals
Modern Humans
Total Cholesterol LDL
 6 
xanthomas, a thickening of the Achilles tendon, and corneal arcus (Damgaard et al., 
2005).  Xanthomas are yellowish lipid deposits under the skin and corneal arcus presents 
as an opaque gray to white coloring around the cornea without causing visual impairment 
(Safarova and Kullo, 2016).   
HeFH is the most prevalent genetic disorder with 1 in 250 individuals afflicted; 
even despite this large occurrence, due to the silent, asymptomatic nature of cholesterol 
buildup over time, many cases also go untreated until the development of cardiovascular 
disease (Casula et al., 2016).  HeFH individuals have an increased risk of suffering from 
cardiovascular events anywhere from 20 to 100 times compared to the genetically 
unaffected population (Casula et al., 2016; Kastelein et al., 2015); this is, in large part, 
because these patient’s ability to clear LDL is impaired.  When LDLRs are impaired, 
LDL levels can rise to anywhere from 160 to well above 300 mg/dL if left untreated 
(Care (UK), 2008).  The Simon Broome Register is a metric developed in the United 
Kingdom for identifying HeFH and is summarized below in Table 2. 
Table 2. British Simon Broome Register summarized (Care (UK), 2008). 
Definite HeFH Probable HeFH 
Tendon xanthomas in: Patient  
First or second degree relative. 
Family History of MIs in: 
First degree relative <60 yrs 
Second degree relative < 50 yrs 
Molecular Genetic Testing: 
Pathogenic, variant in LDLR, APOB, 
PCSK9 
Family history in any first or second 
degree relative of total plasma cholesterol 
>290 mg/dL in an adult or >260mg/dL in 
a child 
Plasma Levels in patient (mg/dL): 
-Total cholesterol >290 in adult or >260 in a child younger than 16 yrs 
-LDL >190 in adult or >155 in a child younger than 16 yrs. 
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Fortunately, LDLR function is not completely inhibited as seen in the much more 
severe HoFH.  Heterozygous FH is a serious condition that can be managed over the long 
term with medication and most importantly lifestyle improvements; treatment with statins 
alone can lead to a 48% decrease in cardiovascular events (Care (UK), 2008). 
HoFH is characterized by unusually early cardiovascular disease and patients with 
this condition often don’t live far into their thirties (Raal et al., 2010).  HoFH patients 
present with significant difficultly clearing LDL cholesterol and thus have very elevated 
levels in their blood.  Similar to HeFH, the most severe form of HoFH is that in which the 
gene for the LDL receptor is mutated causing <2 % activity (Santos, 2018).  In HoFH 
LDL levels usually increase by 4-5 times the normal amount and the standard of care 
usually involves a process known as LDL apheresis (Cuchel et al., 2013).  LDL apheresis 
removes the blood from the body much like dialysis, and filters out the excess LDL 
macromolecules.  Even still, these HoFH patients usually require treatment with statins, 
PCSK9 inhibitors, ApoB inhibitors, MTP inhibitors, or some combination thereof in 
order to correct their over inflated cholesterol levels (Santos, 2018).   
Overall, while it is important to recognize the underlying conditions resulting in 
hypercholesterolemia, it is equally important to examine the treatment options available.  
Modulating treatment parameters such as drug class, dosing, and their use in combination 
could provide an ideal level of cholesterol management for patients suffering from 
hypercholesterolemia.  The drug classes included in this thesis have been studied and 
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proven variably effective in helping to reach these optimal levels of LDL and HDL for 
hypercholesterolemia across its spectrum of causes.   
CVS Risk 
Hypercholesterolemia in otherwise healthy individuals often yields a gradual 
buildup of atherosclerotic plaques in the vasculature.  These plaques are thought in part to 
be a natural immune response to breaks in vasculature, but with the employment of an 
inflammatory response, of leukocytes, and of further amounts of cholesterol, these 
plaques develop into occlusions that cause turbulent flow, stenosis, increased blood 
pressure, and an increased strain on the heart (Zhao et al., 2015)  These gradual buildups 
of plaque often are asymptomatic and do not interfere with everyday life until they’ve 
reached a significant level of occlusion; its then that symptoms such as angina and 
hypertension become apparent.  This silent nature of this condition makes it hard to 
detect until it’s already significantly developed.   
Coronary Artery Disease (CAD) is a generalized term for the disease state of a 
decreased blood flow to the heart itself resulting from atherosclerotic blockage or stenosis 
in the vasculature.  Stenosis, or stiffening of the vasculature, is often seen in conjunction 
with increases in atherosclerosis (Martin et al., 2012).  This stiffening makes blood 
circulation even more difficult and causes an undue stress on the heart as it attempts to 
continue to maintain an appropriate blood flow to the peripheral tissues.  The heart can 
then become hypertrophic further disabling it from carrying out its primary function.  
This entire process becomes broadly classified as congestive heart failure.  CAD is 
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among the most significant contributors to the progression of congestive heart failure and 
cholesterol related fatality (Martin et al., 2012). 
In researching cholesterol levels, it is common to group the occurrences of events 
such as angina and myocardial infarctions (MIs) as cardiovascular events (CE).  CEs are 
events that may cause damage to heart muscle or interrupt blood flow significantly in 
vital organs.  The severity and number of these occurrences in patient populations both 
on a medication and on a placebo can be an important clinical indicator in examining the 
efficacy of a particular drug designed to maintain one’s cholesterol level.   
For thoroughness, it should be mentioned that another acute health risk of 
atherosclerosis is the potential for these plaques to break off and lodge in the smaller 
respiratory or cerebral vasculature causing pulmonary embolism or stroke respectively.  
These two events have not been used as explicit clinical indicators for therapies of 
cholesterol and so they will not be examined in any great detail in this thesis. 
Cholesterol Therapies 
In the liver, HMG-CoA is converted to mevalonate by an enzyme known as 
HMG-CoA reductase.  This has been identified as the key, rate-limiting enzyme in the 
series of chemical reactions that lead to the creation of cholesterol.  Statins have a unique 
role as HMG-CoA inhibitors in decreasing cholesterol production.  Figure 2 depicts the 
pathway by which cholesterol is created in the liver and where statin drugs interact to 
block its synthesis.  This is the main means by which statins treat atherosclerosis, CVD, 
diabetes, and reduce the risk of stroke. 
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Figure 2. Synthesis of non-dietary cholesterol (Cholesterol Synthesis 411, 2002). 
However, statins also have an important second function of reducing 
inflammation by affecting regulatory T cells, and endothelial progenitor cells, nitric oxide 
synthesis, and clotting factors.  These effects, known collectively under banner of 
pleotropic effects, when taken into account alongside their cholesterol lowering influence 
greatly aid in slowing and preventing the process of atherosclerosis and improving 
overall cardiovascular health (Blum, 2014; Zhao et al., 2015).  
PCSK9 is a protein created by hepatocytes in the liver that bind to LDLRs on the 
surface of these hepatocytes.  In binding to these LDLRs via their EGF-A domains, the 
LDL receptor is degraded.  Upon losing LDLRs, the hepatocyte is unable to bind LDL 
for repackaging or excreting leaving the LDL free to build up and contribute to 
atherosclerotic plaques in circulation.  PCSK9 inhibitors are a newer class of drug that 
work to increase the number of LDLR receptors available by preventing PCSK9 from 
interacting with LDLRs (Wan et al., 2017).  Evolocumab is a commonly prescribed 
PCSK9 inhibitor that is administered via subcutaneous injection.  It was approved by the 
FDA in 2015 under the brand name Repatha.  While much research is still ongoing to 
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determine the long term effects of these PCSK9 inhibitors, the initial data suggests a 
great complement to the already powerful therapy provided in statins. 
Apolipoprotein B inhibitors have also become a more prevalently prescribed drug 
for the treatment of hypercholesterolemia.  These drugs are antisense oligonucleotides 
(ASOs) or short, deoxyribonucleotide strands that bind specifically to a complimentary 
mRNA strand and inhibit expression of the Apo B gene.  This inhibits the formation of 
both apoB-48 of chylomicrons and apoB-100, the sole lipoprotein of LDL cholesterol.  
ApoB-100’s function on LDL particles is as a ligand for LDLRs and thus are 
instrumental in the clearance of LDL from the blood (Hussain et al., 1999).  Mipomersen 
has become the leading ApoB inhibitor for treatment of dyslipidemia; it’s long spanning 
development reached clinical trials in 2007 by ISIS Pharmaceuticals and was approved 
by the FDA in 2013 (Ito, 2007). 
LDL apheresis was characterized in 1975 as a potential therapy for 
hypercholesterolemia, and its use has since been proven effective in treating some of the 
more severe cases of hypercholesterolemia, particularly HoFH (Dann et al., 2013).  This 
physical removal of lipoproteins containing cholesterol from the bloodstream began as a 
relatively nonselective process that, through a slow and cumbersome process involving 
heparin-linked agarose beads, removed chylomicrons, VLDL, Lp(a), and LDL (Stefanutti 
and Thompson, 2015).   
Importantly, the new techniques for LDL apheresis do not remove the HDL 
cholesterol, immunoglobulins, or other beneficial proteins from the blood as happens in 
plasmapheresis (Hudgins et al. 2008).  LDL apheresis, MTP inhibitor use, and statin 
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therapy together has proven to be an aggressive, yet effectual combination therapy in 
patients with as severe a cholesterol altering condition as HoFH (Cuchel et al., 2013).  
The FDA has appointed guidelines delineating the parameters necessary for the 
beginning of lipoprotein apheresis.  These parameters are summarized in Table 3.  
Table 3. FDA set parameters indicating use of LDL apheresis therapy (Stefanutti and 
Thompson, 2015). 
Condition Parameters 
HoFH Indicator:  
-LDL > 500 mg/dL after 6 months of diet and maximum tolerated 
therapy 
HeFH Indicators: 
-LDL > 300 mg/dL            
          OR 
-LDL > 200 mg/dL AND documented coronary heart disease 
(Both only after 6 months of diet and maximally tolerated therapy 
 
In children, LDL apheresis on a biweekly basis yields improved plasma LDL 
levels over time spans as long as twenty-one years in HoFH patients (Hudgins et al., 
2008).  LDL lowering by apheresis has long been known to improve endothelial-
dependent vasodilation as well (Tamai et al., 1997). 
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Specific Aims 
1) To examine the causes and types of hypercholesterolemia. 
2) To investigate the available treatments for hypercholesterolemia and their 
mechanisms of action. 
3) To analyze information on the improvement of cardiovascular health of 
patients using combination therapies. 
4) To inspect the side effects of these treatments and to examine any increase in 
their prevalence when used together. 
5) To identify issues with drug adherence and how this affects efficacy. 
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II. STATINS 
Statins have a structure with side chains that mimic HMG and competitively 
inhibit HMG-CoA reductase (Liao and Laufs, 2005).  Statins succeed by binding to 
HMG-CoA reductase’s active site and preventing it from forming a necessary transition 
state (Liao and Laufs, 2005).  These drugs can be administered orally and as such have 
minimal complications with administration such as injection site reactions as seen in 
other cholesterol management therapies. 
Efficacy 
 Statin’s are prescribed by physicians due to their tolerability at high doses, their 
low toxicity, their few side effects, and for their efficacy in reducing the risk of CVD.  
Multiple studies have provided evidence that statin therapy administered as the sole 
therapy has had widespread success in lowering LDL levels when compared to a placebo 
(Centre (UK), 2014).  Table 3 provides an adapted list of the results of multiple studies.  
Each row represents a different study, performed independently, analyzing a different 
type or intensity of statin.  In some cases, such as that of atorvastatin at 10mg medium 
intensity, a parameter is repeated with similar results.  These results document stain 
therapy’s marked ability to decrease LDL compared to the placebo group.  For context: 
2.6mmol/L correlates to 100mg/dL; 5.2mmol/dL equates to 200mg/dL.   
It can been seen below that even at medium or lower intensities, statin therapy is a 
strong therapy for addressing LDL levels.  These studies have indicated, however, that 
moderate to high intensity statin therapy is the most effective and should be the standard 
for care so long as it is tolerable by the patient.  Atorvastatin, pitavastatin, and 
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rosuvastatin have been identified as the most potent of statins due to their higher affinity 
to HMG-CoA reductase, their longer half-life and duration, and their greater lipophilicity 
(Liao and Laufs, 2005).  As such, these drugs are preferred in cases that necessitate high 
dose therapy so long as they are well tolerated.  
 Table 4. LDL Reduction by statin, dose, and intensity compared to placebo (Centre 
(UK), 2014) 
Statin / Dose Intensity Statin Final LDL 
(mmol/L) Mean (SD) 
Placebo Final LDL 
(mmol/L) Mean (SD) 
Atorvastatin / 80mg High 1.89 (0.62) 3.32 (0.75) 
Atorvastatin / 20mg High 2.51 (0.10) 4.37 (0.83) 
Atorvastatin / 10mg Medium 2.11 (0.7) 3.12 (0.8) 
Atorvastatin / 10mg Medium 2.32 (0.72) 3.27 (0.81) 
Atorvastatin / 10mg Medium 1.97 (0.47) 2.84 (0.91) 
Pravastatin / 40mg Low 3.1 (0.9) 3.9 (0.1) 
Pravastatin / 40mg Low 3.11 (0.59) 4.31 (0.56) 
Pravastatin / 20mg Low 2.98 (0.52) 3.64 (0.52) 
Simvastatin / 80mg High 1.91 (0.49) 3.26 (0.49) 
Simvastatin / 20mg Medium 2.64 (0.96) 3.76 (0.83) 
Simvastatin / 10mg Low 2.33 (0.49) 3.43 (0.56) 
Rosuvastatin / 10mg High 2.03 (1.15) 2.5 (0.7) 
 
The lowering of LDL levels and cardiovascular events undoubtedly are the 
significant contributors to the stark decrease in all-cause mortality seen in patients 
prescribed statins compared to placebo.  All-cause mortality is defined as the number of 
deaths in a given study from any related condition.  In one analysis, the deaths from all-
cause mortality, CV mortality, non-fatal MIs, and stroke were examined.  In combining 
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multiple studies of statins including these parameters, one finds a stark decrease in the 
number of deaths in both the immediate, short term (1-3 years) and over a longer course 
of administration (>3 years) (Centre (UK), 2014).  These results are condensed and 
summarized in Table 4. 
Table 5. All-cause mortality, CV mortality, non-fatal MI, and stroke with short and long 
term treatments with statins vs placebos. (Centre (UK), 2014)  
 Short Term (1-3 yrs) Long Term (>3 yrs) 
Statins Placebo Statins Placebo 
Occurrences 352 450 3983 4513 
Total Participants 13364 12938 47058 47112 
% Incidence 2.63% 3.48% 8.46% 9.58% 
 
Bucking the trend of analyzing statin’s in at risk patient populations as a 
preventive measure, a study known as the Myocardial Ischemia Reduction with 
Aggressive Cholesterol Lowering (MIRACL) study sought to examine the use of statins 
following an acute coronary syndrome (ACS) and to examine its effects on LDL levels 
(Schwartz et al., 2001).  ACS is often a condition that results from the breakage of an 
arterial wall and the release of a plaque into systemic circulation and eventually lodging 
in coronary circulation.  Previous studies had excluded applicants with previous ACS 
from participating for want of pure results on statin’s LDL cholesterol managing 
capability.  This study used patients with previous ACS as its target patient population so 
that they could examine the likelihood of recurrence.  This study culminated in a 25-30% 
reduction in ischemic events and hospitalization in patients taking atorvastatin compared 
to the placebo group coupled with stark drops in LDL levels (Schwartz et al., 2001).  This 
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significant decrease in cardiovascular events contributes to the wide base of evidence 
proclaiming the efficacy of statins on cardiovascular health. 
Pleiotropy 
Endothelial function, platelet function, smooth muscle proliferation, and plaque 
stabilities are all key characteristics of the development of atherosclerosis and 
cardiovascular disease and each is modulated by statins (Liao and Laufs, 2005).  Vascular 
endothelium acts not only as the important outermost barrier between the blood and the 
tissues that it nourishes, but also as a contractile wall that contributes to the circulation 
(Kureishi et al., 2000).  Nitric oxide (NO) is a well-known, crucial compound released 
from the endothelium that is largely responsible for local vasodilation  (Kureishi et al., 
2000).  One study investigated the use of simvastatin in activating the Akt pathway that 
ends in the phosphorylation of an endothelial nitric oxide synthase (eNOS) and found that 
this statin directly phosphorylate Akt and increase its activity (Kureishi et al., 2000).  In 
this way, NO is produced by the endothelial cells which functions to improves platelet 
adhesion, inflammatory response, and smooth muscle cell proliferation (Liao and Laufs, 
2005).   
Outside of the activation of Akt pathway, statins also induce angiogenesis by 
quickening the release of endothelial progenitor cells (EPCs) from the bone marrow 
(Vasa et al., 2001).  These EPCs increase revascularization and vascular stability in 
already existing vasculature and thus contribute to the overall improved cardiovascular 
health (Vasa et al., 2001).   
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In addition to their Akt pathway mechanism, their EPC increasing ability, and 
their LDL cholesterol lowering, statins have been indicated as capable of decreasing 
macrophages that express matrix metalloproteinases from accumulating at plaque sites 
(Aikawa et al., 2001).  In doing so, the plaque makeup and severity of its buildup is 
altered and the blockage of circulation is lessened. 
Side Effects and Contraindications 
Use of statins is very rarely met with unfavorable consequences even when they 
are administered at very high doses.  They are, however, contraindicated for use 
concomitantly with cyclosporine, macrolide antibiotics, some anti-fungal agents, or 
cytochrome P-450 inhibitors (NCEP ATP-III Cholesterol Guidelines -- Cholesterol 2.0 - 
SCYMED, 2002).  With over 100 million worldwide annual prescriptions for statins, its 
side effects have become as well documented as has the capability for lowering LDL.  
Statins’ largest noted side effects are those involving myopathic events.  These are 
subclassified as myalgia, myositis, and rhabdomyolysis.  The distinction between each of 
these terms as determined by the American College of Cardiology, American Heart 
Association, and Nation Heart, Lung and Blood Institute (ACC/AHA/NCBI) is 
summarized in Table 5. 
 
 
 
 
 
 19 
Table 6. Distinguishing the myopathic events secondary to statin therapy (Pasternak et 
al., 2002). 
Term Definition 
Myopathy Broadly, a disease of the muscle 
Acquired or inherited 
Myalgia Muscle weakness or aching. 
No CK elevation 
Myositis Muscle ache, weakness, or other symptoms 
CK Elevation  
Rhabdomyolysis Muscle weakness, ache, or other symptoms 
Significant CK elevation of  >10x normal 
Usually with brown urine and urinary myoglobin 
 
The underlying pathology behind these muscle disorders in association with 
statins is relatively unknown per the ACC/AHA/NCBI.  It has been proposed that statin 
use causes a ubiquinone insufficiency in the muscle cells.  Due to their vital role as an 
energy source intracellularly, this deficiency could inhibit cellular respiration  (Flint et 
al., 1997).  Another theory suggests that cytochrome P-450s interact unfavorably with 
statins although this is partially contrived from the documented increased toxicity of 
administering statins alongside substances broken down by the same cytochromes 
(Davidson, 2000).    
What is known is that the breakdown of skeletal muscle is measurable in the 
blood via an elevation of skeletal muscle protein levels known as creatine kinase (CK).  
These muscle disorders collectively affect only a small percent of the general population 
and are reported at 4-5%.  Many studies find the number of complaints for patients taking 
statins residing around double that (Nichols and Koro, 2007); still others record 
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myopathic complaints by patients as high as 21% (El-Salem et al., 2011).  This study 
indicated that these feelings of muscle pain or weakness were more common in patients 
taking statins that had a history of diabetes or stroke (El-Salem et al., 2011).   
The most serious form of myopathy secondary to statin therapy is 
rhabdomyolysis.  As shown in Table 5, CK levels as high as 10 times the normal amount 
coupled with muscular events are the parameters by which one can identify 
rhabdomyolysis; while this event is potentially fatal, it occurs in statin patients in less 
than 4 of every 100,000 cases per year and this number is not significantly increased 
when compared to the general population (Nichols and Koro, 2007).  The sole exception 
to this was seen with cerivastatin which saw significant increases of 16 to 80 times higher 
in number of cases of rhabdomyolysis (Pasternak et al., 2002).  Only upon elevation of 
CK levels or muscle pain and weakness is the dose modulated or other therapies 
explored.   
Elevations in amino transaminases (ALT) levels in the liver have also been 
correlated with 0.5-2.0% of cases involving statin therapy (Pasternak et al., 2002) .  This 
has been shown, however, to be dose dependent and reversible with a decrease in the 
dose.  This has not been directly connected to hepatotoxicity.   
Adherence 
Drugs such as statins are dependent on long term, regular administration in order 
to maintain their effectiveness.  It has been shown that even maintaining an 80% or lower 
adherence to the set timelines for administration can reduce statin effectiveness 
significantly (Casula et al., 2016).  Studies such as the aforementioned MIRACL study 
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reported disqualified subjects of up to 10% due to inability to adhere to the regular 
administration of atorvastatin (Schwartz et al., 2001). 
Adherence is a complicated thing to measure as it often relies on self-reporting by 
the patient.  It has been shown that the majority of adherence percentages in studies hover 
around 90% when self-reported (Casula et al., 2016).  One investigation sought to 
quantify the issue of adherence and tracked the filling of statin prescriptions each month; 
they assigned this statistic the title Medication Possession Ratio (MPR).  This statistic 
was: the ratio of the days a drug covered over the days of observation turned into a 
percentage.  100% was the upper limit.   
 	
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The study indicated that an MPR over 80% correlated with appropriate or optimal 
adherence (Casula et al., 2016).  Their results indicated that the average MPR over the 
course of a year was 69% and that many subjects dropped or discontinued treatment at an 
average of eight months into statin therapy (Casula et al., 2016). 
A second, retrospective study in Italy showed that only 47.5% of newly 
prescribed statins were followed up on and refilled.  Worse still is that 59.5% of those 
that refilled their prescriptions took it <50% of the time (Corrao et al., 2010).  Of interest, 
25% of those that did not follow up for treatment had low risk of ischemic heart disease 
(Corrao et al., 2010).  This indicates that severity of condition is a compelling factor in 
determining level of adherence in a patient.   
Failure to adhere to statins regiments stems from several factors.  The first and 
perhaps most obvious is cost.  While detailed investigation into the cost of statin therapy 
 22 
is beyond the scope of this thesis, it is important to note that due to the silent nature of 
dyslipidemia, patients are less likely to spend money regularly out of pocket on a drug 
that doesn’t ameliorate a discomfort, pain, or deformity.  It has also been argued that the 
ineffectiveness in prescription of statin drugs resides in physicians prescribing too low a 
dose.  In Casula’s study, it was determined that 58% of patients were started on too low a 
dose initially and required more rigorous treatment (Casula et al., 2016).  
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III. STATINS AND PCSK9 INHIBITORS 
 Even before the approval of evolocumab in 2015 there was an immense interest in 
the research of potential concurrent treatment of hypercholesterolemia with the use of 
statins and PCSK9 inhibitors.   
Cholesterol Lowering Efficacy 
The DESCARTES study examined the effects of evolocumab in patients over the 
course of a 52 week period (Toth et al., 2018). This study used study groups set at statin-
free, low intensity statin, high intensity statin, and statin with ezetimibe for analysis.  It 
administered evolocumab every month and saw a -44% change in LDL levels compared 
to a +6.4% change in the placebo group (Toth et al., 2018).  While this is significant, this 
study also recognized an increase in HDL levels in the evolocumab group by +9.4% 
compared to -0.1% in the placebo group  (Toth et al., 2018).  The mechanism behind the 
increase in HDL has not yet been identified, but its occurrence further increases 
confidence in the use of PCSK9 inhibitors in cholesterol management cases.  While this 
study did have control groups for patient populations on statins, they did not provide any 
of their own data for their combined efficacy in reducing LDL compared to individually, 
they did express in their discussion that the adjuvant use of evolocumab with statins 
would provide a substantial reduction in LDL (Toth et al., 2018).  
An earlier study, LAPLACE-2 clinical trial, used evolocumab as a singular 
therapy in patients with LDLs 150 mg/dL or greater, as a supplement to patients with 
nonintensive statin therapy and an LDL level of 100 mg/dL or greater, and as a 
supplement to intensive statin therapy and an LDL level of 80 mg/dL or greater 
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(Robinson et al., 2014).  The goal of this twelve week study was to determine its ability 
to lower LDL levels independently in hypercholesterolemia patients and also alongside 
statin therapy.  The results showed a decrease in LDL levels, with the starkest decreases 
occurring in concurrence with high or moderate-intensity statins.  The results are 
summarized by mean % Change in LDL levels and mean LDL decrease in Table 6.  
Table 7. Mean LDL decrease and % decrease at 12 weeks of with administration of 
evolocumab every 2 weeks in conjunction with moderate and high intensity statin 
treatment (Robinson et al., 2014).  
 High-Intensity Statin 
Atrovastatin (80mg) Rosuvastatin (40mg) 
LDL-C vs placebo vs Ezetimibe vs placebo 
% change at wk 
12 
-76.3 (-86.9 to -65.7) -47.2 (-57.5 to -
36.9) 
-68.3 (-77.0 to -59.6) 
Change at wk 
12 (mg/dL) 
-71.7 (-84.4 to -59.0) -49.0 (-61.5 to -
36.6) 
-57.2 (-65.1 to -49.4) 
 Moderate-Intensity Statin 
Atrovastatin (10mg) Simvastatin 
(40mg) 
Rosuvastatin 
(5mg) 
LDL-C vs placebo vs Ezetimibe vs placebo vs placebo 
% change at wk 
12 
-71.4 (-77.6 
to -65.3) 
-39.6 (-45.8 to 
–33.4) 
-70.6 (-76.7 to -
64.4) 
-68.2 (-74.7 to -
61.7) 
Change at wk 
12 (mg/dL) 
-85.5 (-95.2 
to -75.9) 
-46.8 (-56.6 to 
-37.1) 
-79.0 (-87.5 to –
70.4) 
-77.1 (-86.2 to -
67.9) 
 
With patients on moderate-intensity statin treatment, the addition of evolocumab 
every two weeks brought 88-94% of them below the 70 mg/dL LDL level threshold, 
down from the baseline mean of 115 to 124 mg/dL (Robinson et al., 2014).  Similar 
decreases were found in those with high intensity statins.  This finding provides strong 
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evidence for the concurrent use of these evolocumab and moderate to high intensity 
statins for the express purpose of decreasing LDL. 
Similar results were found in studies for a separate type of PCSK9 inhibitor 
known as alirocumab.  This drug as similarly administered to patients with HeFH every 
two weeks.  This experiment largely focused on the goals of decreasing LDL using 
alirocumab and statin therapies together over a longer term of 78 week period.  Its results 
echo those of Robinson and Toth with the significant benefit of lowering LDL levels by 
50-60% below their baseline and with few side significant side effects or deaths 
(Kastelein et al., 2016).  
CVS Occurrences 
 While the goal of lowering LDL cholesterol is undoubtedly of utmost importance, 
the purpose behind this goal is to lower the likelihood of adverse cardiovascular events.   
In The ODDYSSY LONG TERM Trial, not only were the levels of LDL cholesterol 
examined, but perhaps more importantly, an ad hoc analysis was performed of the 
cardiovascular events suffered after the 78 weeks period.  The study population included 
adults over 18 years in age with HeFH, a history of CEs, and whose LDL levels remained 
greater than 70 mg/dL.  All patients were taking statin therapy at the maximal tolerable 
dose (Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events | 
NEJM, 2015).  Similar to the study performed by Kastelein et all, this study used 
alirocumab in doses every two weeks and closely followed LDL, side effects, and CVS 
effects in its sample populations. 
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 The endpoints for cardiovascular health included death from coronary heart 
disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable 
angina requiring hospitalization (Efficacy and Safety of Alirocumab in Reducing Lipids 
and Cardiovascular Events | NEJM, 2015).  It is notable that during the 78 week trial the 
number of total cardiovascular events was more or less consistent between the placebo 
group and the alirocumab group at 5.1% occurrence with placebo and 4.6% for those 
taking the PCSK9 inhibitor.  However, deaths from major cardiovascular events was 
reduced by almost half in those patients taking alirocumab (down to 1.7% compared to 
3.3%) (Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events 
| NEJM, 2015).   
 A meta-analysis of data from multiple studies performed by the American College 
of Physicians reviewed 24 different PCSK9 inhibitor studies.  This meta-analysis yielded 
differing results from those of the ODDYSSEY LONG TERM Trial analysis.  This meta-
analysis showed a statistically insignificant difference in the number of cardiovascular 
mortalities between PCSK9 inhibitor treatment and placebo groups (Effects of PCSK9 
Antibodies in Adults With Hypercholesterolemia | Annals of Internal Medicine | 
American College of Physicians, 2015).  It should be pointed out that these studies all 
included PCSK9 inhibitor treatments, but varied amongst other parameters such as the 
use of statins and comparisons with ezetimibe.  It is likely that the population 
demographics and prior conditions between trials also varied.  One point of interest, 
however, is that this meta-analysis showed a significant statistical decrease in MIs for 
patients taking PCSK9 inhibitors at 0.58% compared to 1.00% for placebo patient 
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populations (Effects of PCSK9 Antibodies in Adults With Hypercholesterolemia | Annals 
of Internal Medicine | American College of Physicians, 2015). 
These studies point markedly in support of combination use of PCSK9 inhibitors 
alongside high intensity statin therapy for maintaining long term cardiovascular health.  
The number of fatalities associated with hypercholesterolemia and cardiovascular disease 
could theoretically be dropped significantly if this approach is adopted.  
Side Effects 
 Documented side effects of combination therapy of statins and PCSK9 inhibitors 
included an increase in myalgia, neurocognitive effects, injection-site reactions, and 
ophthalmologic events.  The neurocognitive effects included confusion, amnesia, and 
memory impairment (Robinson et al., 2014).  Robinson’s study provides strong evidence 
for the increase in these side effects in patients taking alirocumab when compared to the 
placebo.  These results are summarized in Table 7. 
 
Table 8. Percent occurrences of common side effects attributed to alirocumab therapy 
alongside statin use compared against statin use with placebos (Efficacy and Safety of 
Alirocumab in Reducing Lipids and Cardiovascular Events | NEJM, 2015).  
Adverse Events Alirocumab Placebo 
Injection-site reactions 5.9% 4.2% 
Myalgia 5.4% 2.9% 
Neurocognitive events 1.2% 0.5% 
Ophthalmologic events 2.9% 1.9% 
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Because both the placebo and the alirocumab groups were taking high intensity 
statins, the increase in myalgia noted in patients suggests that PCSK9 inhibitors somehow 
exacerbate this already well documented side effect of statin therapy in patients.  None of 
these adverse events resulted in discontinuation of their involvement in the study, and 
none yielded long term negative effects for the patients. 
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IV. STATINS AND APOB INHIBITORS 
 With increased understanding behind the mechanisms by which LDL increases 
and is eliminated in the body, research into treatment options for hypercholesterolemia 
continue to expand; ApoB inhibitors such as mipomersen have been studied as a 
powerful adjunct to statin therapy.  In particular, ApoB inhibitors have been studied for 
use in HoFH patient populations.  The largest cause of HoFH is a mutation affecting the 
number or ability of LDLRs; this causes an insufficient response through statin or PCSK9 
therapy.  The increase in LDLRs proves to be minimally effectual when the number of 
LDLRs are at such a severely low level to begin with.  Summarized, when the LDLRs 
don’t work as they’re supposed to, increasing the number won’t help (Raal et al., 2010).   
Cholesterol Lowering Efficacy 
 The goal of ApoB inhibitors is to lower the amount of LDL not by increasing its 
clearance, but rather by limiting its creation.  ApoB inhibitors inhibit the production of 
the sole apolipoprotein associated with LDL, ApoB-100.  A concern with this treatment 
in the preclinical stages was whether or not it would also inhibit apolipoprotein B48.  
While it has been shown that it could inhibit apoB-48, mipomersen is specific for the 
liver as opposed to the gut and so there has been no evidence of gut malabsorption 
associated with inhibition of apoB-48 (Raal et al., 2010). 
 One study performed by Frederick Raal and Raul Santos examined patients aged 
12 years and older diagnosed with HoFH (Raal et al., 2010).  This study included only 
patients on maximum tolerated lipid-lowering drugs with statins being the most 
predominant; it measured baseline and final hepatic fat content via MRI, ALT levels, and 
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of course LDL concentrations in its participants.  HDL and VLDL were also taken into 
account.  Patients were given a weekly dose of 200 mg mipomersen or placebo and it was 
found that the mipomersen group’s LDL levels dropped by 25% (Raal et al., 2010).  
While few patients met their therapeutic targets for LDL cholesterol concentration, a 25% 
decrease in LDL in HoFH patients could contribute to better overall health and a lower 
risk of cardiovascular events. 
 A separate study sought to examine the improvement mipomersen might have on 
patients afflicted with HeFH already taking maximally tolerated lipid-lowering therapies 
including statins.  Similar to Raal’s study, patients were given either weekly 
subcutaneous mipomersen at 200 mg or a placebo.  This study took place over 26 weeks.  
The results showed a similar result with LDL levels dropping by 28% from the baseline, 
however 45.1% of patients on the mipomersen group met the LDL goal of dropping 
below 100 mg/dL compared to 4.9% of those on the placebo (Stein et al., 2012).  This 
contrasts with Raal’s results in patients with HoFH in which “most” patients did not meet 
their therapeutic targets for LDL cholesterol (actual number of patients not provided) 
(Raal et al., 2010). 
CVS Occurrences 
 As mentioned, the lowering of LDL levels has a strong correlation with the 
decreased likelihood of CEs occurring.  Unique to ApoB-100 inhibitors, however, is their 
effect of reducing lipoprotein(a) (Lp(a)) levels.  Lp(a) is an LDL-like particle created in 
the liver and contains both apolipoprotein B100 and a glycoprotein known as 
apolipoprotein(a) (Marcovina and Koschinsky, 1998).   
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While it has been correlated as a cardiovascular risk indicator, studies such as one 
conducted in Copenhagen drew an absolute and relative relation between Lp(a) and the 
occurrences of MIs or the development of cardiovascular disease (Kamstrup et al., 2008).  
It determined a 2.3 fold increase risk of cardiovascular disease in patients whose Lp(a) 
levels fell within the 90th percentile (Kamstrup et al., 2008).  Lp(a)’s mechanism of action 
in contributing to cardiovascular disease reside in its role as a promoter of thrombosis, 
inflammation, and foam cell formation upon entering the arterial intima (“Lipoprotein(a) 
Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular 
Mortality”, 2009).   
Patients in Raal’s mipomersen group also saw lipoprotein(a) levels reduce 
significantly (Raal et al., 2010).  This provides evidence for the use of mipomersen as a 
potential therapeutic for targeting Lp(a), allowing the drug to serve a dual purpose of 
lowering both LDL and Lp(a).  Beyond the effect to cardiovascular health associated with 
the decrease in LDL level and with Lp(a), patients in mipomersen studies did not 
experience significant cardiovascular events that could be attributed to the dug 
administration or the parameters of the studies (Raal et al., 2010; Stein et al., 2012). 
Side Effects 
 In several of the studies, cases of injection-site reactions, ALT increases, and flu-
like symptoms were reported.  Generally, the total number of injection site reactions in 
the mipomersen group was anywhere from two to three-times more prevalent than those 
of the placebo group (Raal et al., 2010; Thomas et al., 2013; Stein et al., 2012)   
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The increases in ALT in general were seen in 30.5% of the mipomersen group 
compared to only 13.5% of the placebo, however ALT levels of >3 times the upper limit 
of normal was shown to be prevalent in 10% of mipomersen group compared to none in 
the placebo group (Thomas et al., 2013).  ALT levels usually rise with the breakdown of 
liver cells.  This can be indicative of liver disease, and although these levels of ALT are 
indeed much above normal levels, it is unclear as of yet what the clinical relevance of this 
finding is.  One might suspect the prevalence some sort of liver steatosis or fibrosis from 
a developing fatty liver, but biopsies from one study’s mipomersen-treated subjects 
showed minimal inflammation and little to no fibrosis (Thomas et al., 2013). 
The prevalence of influenza-like symptoms across all of the mipomersen studies 
is a strong indicator of its frequency as a side effect of this treatment.  In one study in 
particular, flu-like symptoms occurred in 34.3% of the mipomersen as opposed to only 
21.2% of the placebo group (Thomas et al., 2013); of note is that in this same study the 
dropout rate for the mipomersen group was 43% with more than half of those attributed 
to adverse effects while the percentage of dropouts from the placebo group was only 
17%.  It’s reasonable to argue that mipomersen treatments present a large degree of 
discomfort for patients from the prevalence of injection sight reactions and flu-like 
symptoms.  
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V. STATINS AND EZETIMIBE, THYROMIMETICS, AND MTP INHIBITORS 
Ezetimibe 
 Statin therapy with ezetimibe has been established as a common therapy for 
further lowering cholesterol and decreasing cardiovascular risk.  Ezetimibe is a 
cholesterol uptake inhibitor that acts on the Niemann-Pick C1-like1 protein of the 
intestine (Pisciotta et al., 2007).  Ezetimibe’s effectiveness in limiting the level of 
cholesterol in the body is derived from its mechanism of restricting the amount of biliary 
cholesterol absorbed in the intestine via the diet without affecting the amount of 
triglycerides absorbed (Davidson et al., 2002).  In this way ezetimibe’s upside as a 
cholesterol therapy is restricted, as most cholesterol is synthesized by the liver and not 
taken up via diet.   
One study showed ezetimibe having the capability of decreasing LDL levels by an 
additional 34% upon addition to statin treatment when compared to high intensity statin 
treatment alone (Davidson et al., 2002).  Intriguingly, another study indicated that the 
type of LDLR mutation present in their HeFH patients did not seem to matter with 
regards to LDL lowering ability of statins and ezetimibe (Pisciotta et al., 2007).  The 
LAPLACE-2 study of evolocumab showed even more optimistic results with treatments 
of ezetimibe administered every two weeks.  Here, it was shown to have a 47.2% 
decrease from the baseline used together with high intensity statins and a 39.6% decrease 
when used with moderate-intensity statins (Table 6) (Robinson et al., 2014).  Also of note 
in this combination treatment is an increase in HDL levels by ranging from 8-11% adding 
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to the already well documented positive effects of ezetimibe treatment with statins 
(Davidson et al., 2002). 
Adverse Effects 
Factors such as myopathy, CK levels, ALT levels were all examined throughout 
these studies as they are common side effects of statin therapy.  Multiple studies using a 
variety of statin intensities have noted that the addition of ezetimibe has not yielded any 
significant statistical increase in the occurrence of any of the aforementioned adverse 
effects (Ballantyne et al., 2004; Davidson et al., 2002; Pisciotta et al., 2007).  Overall, it 
appears that this combination’s safety parameters more or less echo those of statin 
therapy alone, while yielding larger decreases in LDL levels.   
Thyromimetics 
 Thyroid hormone has long been known to have cholesterol lowering properties; as 
early as 1950’s desiccated thyroid was given to patients to examine its lipid lowering 
effects.  It was found that in low doses there was lipid improvement, but in higher doses 
patients suffered from metabolic shifts, tachycardia, along with a slew of other 
hyperthyroid-related conditions (Tancevski et al., 2009).  Since then, research and 
development has been put into developing compounds that mimic some of the lipid 
lowering properties while steering clear of those related to the aforementioned side 
effects.   
In the years since this early adventure into the world of thyromimetics, 
Eprotirome and Sobitirome have been the two drugs that have come closest to fruition.  
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While both drugs showed significant ability to lower LDL, their side effects poised too 
significant of detriments to continue development (Elbers et al., 2016).  The data 
regarding their efficacy and side effects are summarized in Table 8. 
Table 9. Failed and future thyromimetics, LDL lowering capabilities, and adverse effects 
(Elbers et al., 2016).  
Drug Stage of Development Lipid Lowering 
Profile 
Adverse Effects 
Sobetirome Terminated after phase 
1 due to serious effects 
noted in eprotirome 
Decreased LDL 
up to 41% 
N/A, 
Generally well tolerated 
Eprotirome Terminated during 
phase 3 clinical study 
in patients with FH 
Decreased LDL 
by 22-32%, ApoB 
by 21-31% 
Increases in ALT levels  
Deleterious effects on 
cartilage in canines 
MGL-3196 Currently in phase 1 May decrease 
LDL up to 30%, 
ApoB up to 60% 
No evidence for 
negative effects on heart 
or liver to date. 
 
MTP Inhibitors 
In the liver and intestine, microsomal triglyceride transfer protein (MTP), is a 
protein that aids the transfer of lipid to ApoB in the hepatocyte and the assembly of 
chylomicrons in enterocytes in the intestine.  Abetalipoproteinemia is a disorder in which 
the MTP gene is defective and cannot produce functional MTP proteins; interestingly, 
subjects with this disorder present with lowered LDL levels and steatosis in the liver 
(fatty liver) (Hussain and Bakillah, 2009).  This disorder presents a model of the LDL 
effects and side effects associated with high doses of MTP inhibitors; these therapies 
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could mimic the natural effects of abetalipoproteinemia and effectively slow lipoprotein 
and chylomicron production.   
Lomitapide was approved by the FDA in 2012 as an MTP inhibitor; it was 
approved for use in patients with HoFH for its LDL lowering ability (Yahya et al., 2016).  
As an MTP inhibitor, it inhibits the production of both ApoB 100, found on VLDL, IDL, 
and LDL, and ApoB 48 which is found on chylomicrons in the gut.  Cuchel’s study 
shows the effectiveness of Lomitapide in HoFH patients as both a combination with LDL 
apheresis and as used in conjunction with statin therapy as 27 of the 29 participants were 
taking statins throughout the trials (Cuchel et al., 2013).   
The trials that used statins and lomitapide found even better responses by week 26 
with two thirds of the patients having decreases in LDL of at least 25% one third of them 
showing a 50% lowering from the baseline (Cuchel et al., 2013).  These results point to 
the efficacy of these treatment plans used in conjunction with each other for HoFH 
patients. 
Adverse Effects 
It has been shown to lower LDL levels, but it has been linked with the adverse 
effects of liver steatosis, decreased HDL, alongside increased ALT levels (Cuchel et al., 
2013; Yahya et al., 2016).  Despite the evidence that use increases liver steatosis, patients 
can decrease this likelihood and the chances of developing liver toxicity with a low-fat 
diet (Cuchel et al., 2013; Yahya et al., 2016).  Lomitapide also has been shown to have an 
HDL lowering effect on its patients (Yahya et al., 2016)  While the lowering of HDL in 
patient populations suffering from hypercholesterolemia is not ideal, this HDL lowering 
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not significant enough to outweigh great benefit derived from such a large decrease in 
LDL.  This is summarized in Figure 3. 
 
Figure 3. Relative decreases in LDL and HDL levels in patients with HoFH 
treated with Lomitapide (Yahya et al., 2016).  
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CONCLUSION 
The question remains: what medications should physicians prescribe and to which 
patients?  Each time this question has been addressed it has yielded somewhat different 
results; as such, it is not something that can be neatly summed up and wrapped in a bow 
from this thesis.  With any luck, however, the reader can come away with a more 
thorough understanding of the therapies available to patients suffering from 
hypercholesterolemia.  Beyond just their individual effectiveness, each therapy’s use in 
conjunction with statin therapy was reviewed.  If nothing else, the large amount of 
resources available to patients and physicians alike should provide the thrilling 
reassurance that hypercholesterolemia is not a condition that is taken lightly by the 
medical community. 
Overall, it remains true that statins should continue to remain the first line of 
defense against dyslipidemia.  The amount of evidence that shows the efficacy of high 
intensity statin therapy in managing LDL cholesterol is overwhelming.  Beyond just the 
significant decreases in LDL levels, statins have pleiotropic effects of activating the Akt 
pathway and increasing the production of nitric oxide, increasing the number of EPCs 
released from the bone marrow, and diminishing the integrity of plaques building up by 
decreasing the number of MMP containing macrophages (Aikawa et al. (2001; Kureishi 
et al., 2000; Liao and Laufs, 2005; Vasa et al., 2001).   
These effects lead to the beneficial effects of improved endothelial function, 
plaque diminishment, anti-inflammatory properties, and platelet function.  Such desirable 
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clinical improvements stand as testaments to the enormity of benefits in beginning high 
intensity statin therapy for patients suffering from hypercholesterolemia. 
Statin therapy is not, however, without its drawbacks.  Patients on high intensity 
statins can suffer from myopathy and elevated liver enzymes.  While these occurrences 
are not ideal, they happen at such minimal rates that the benefits of therapy far outweigh 
the downsides.  Statin’s few side effects and large therapeutic window provide physicians 
with a lot of room to modulate doses to best meet the needs of each patient.  Combination 
therapy should only be considered in cases when high intensity statin therapy is not well 
tolerated or does not reach the target LDL goal. 
While every patient is different and will respond to these medications in a unique 
way, the overall consensus is that combination therapy has great potential to lower LDL 
cholesterol and curb the occurrences of cardiovascular events.  The already regular 
combination of statins with ezetimibe in treating dyslipidemia is a step in the right 
direction.  With increases in LDL lowering efficacy increased by 34%, ezetimibe proves 
a solid accent to statins (Davidson et al., 2002).   
These results, however, fall somewhat shorter than those involving the 
combination with drug classes of PCSK9 inhibitors and apoB inhibitors.  Perhaps the 
largest benefit of this combination therapy of ezetimibe and statins is the lack of side 
effects beyond those already attributed to statins alone.  In a risk-benefit analysis 
comparing this lack of side effects and great upside against those of PCSK9 inhibitors 
and apo B inhibitors might favor ezetimibe, but currently this is more speculative than 
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based in any hard evidence; this reasoning may, however, provide some little rationale 
for why this combination is so often chosen by physicians. 
With reductions in LDL as high as 60% from their baseline and with 80-90% of 
patients’ LDL cholesterol tamping down below the 70 mg/dL threshold when used with 
statins, PCSK9 inhibitors are considered a therapy with a lot of upside (Robinson et al., 
2014; Toth et al., 2018).  While confusion and other neurocognitive effects, ophthalmic 
events, the increase in myopathic events all occur in small percentages of patients taking 
PCSK9 inhibitors, its ability to slightly increase HDL levels while significantly lowering 
LDL levels tip the balance in favor of its regular use in cholesterol management.  This 
concurrent use should be considered by physicians a more aggressive, yet effective 
regulator of cholesterol.   
The use of ApoB inhibitors alongside statins has proven to be effective in terms of 
LDL goals, but doesn’t seem to be any more effective than what was seen in combination 
with PCSK9 inhibitors.  While both have the unfortunate side effects of injection site 
reactions, ApoB inhibitors such as mipomersen also have been shown to have an 
increased likelihood of the development of flu like symptoms its patients.  This has been 
shown to prevent adherence to treatments as many patients dropped out of studies citing 
discomfort or adverse effects as their primary reason while on the mipomersen treatment.  
Mipomersen does, however, carry with it a novel approach to lowering LDL in that it 
does not rely on the presence or functionality of the LDLR receptor, but rather prevents 
the formation of the apolipoprotein B100 and thus the LDL macromolecule itself.  This 
upside should be considered in patients with HoFH, a disease whose issue typically 
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resides with the functioning of the LDLRs.  Another potential benefit to the use of this 
medication in conjunction with statins is its ability to lower Lp(a).  This has been strongly 
correlated with decreased risk of developing cardiovascular disease.   
Thyromimetics, to date, have not lived up to the hubbub surrounding them since 
their conception almost fifty years ago.  With side effects such as severe liver toxicity and 
cartilage breakdown, multiple thyromimetics have been discontinued before finishing 
clinical trials and coming to market.  A new drug, MGL-3196 is currently undergoing 
testing to see if it can avoid the pratfalls of its predecessors Eprotirome and Sobitirome 
while still maintaining LDL lowering capabilities.  
Patients afflicted with the genetic disorder HoFH should consider the therapies of 
LDL apheresis, statins, and/or MTP inhibitors such as lomitapide for managing their LDL 
levels.  LDL apheresis has become further specialized since its discovery in the 1970’s 
and is now viewed as more of a last resort or extreme type of therapy by the FDA 
(Cuchel et al., 2013; Stefanutti and Thompson, 2015).  Long-term analysis of the CVS 
risks associated with lomitapide have not been performed, but this is more a result of the 
rarity of the disease and the short life span associated with HoFH.  The CVS benefits of 
lomitapide have been largely extrapolated from its proven ability to lower LDL 
cholesterol.  HDL decreases were similarly shown, but the possible negative effects were 
speculated to be outweigh by the significant decreases in LDL (Cuchel et al., 2013; 
Yahya et al., 2016).  
Two potential issues of concurrent use of statins and other medications is that of 
cost and adherence.  While the cost is significantly cheaper than that of a bypass surgery, 
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a stent, or other surgical procedure, extensive hospitalization, and then prescriptions, it is 
more difficult to convince one’s patients of this side of the coin until they are faced with 
it.  Alongside the issue of cost, it’s been well documented that adherence to statin’s is the 
greatest cause for inefficacy in patients prescribed it.  It would not be a stretch to reason 
that the addition of other medications (particularly ones that involve subcutaneous 
injections such as PCSK9 inhibitors and mipomersen) would be similarly ill adhered to.  
What it might take to correct this is an issue that goes beyond this thesis; however it 
should convince the reader of the importance of educating one’s patients on the reality of 
their condition whether they’re young, old, diabetic, hypertensive, simply at risk, or have 
already suffered a cardiovascular event.  
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